Precigen Profit Margin 2012-2021 | PGEN
Current and historical gross margin, operating margin and net profit margin for Precigen (PGEN) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Precigen net profit margin as of June 30, 2021 is -107.46%.
|Precigen Annual Profit Margins
|Precigen Quarterly Profit Margins
||Medical - Biomedical and Genetics
Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.